Icahn School of Medicine at Mount Sinai-ko ikertzaileekin lankidetzan egindako argitalpenak (25)

2024

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis

    International Journal of Infectious Diseases, Vol. 131, pp. 173-179

  3. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

2021

  1. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

  2. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

  3. The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study

    Schizophrenia Research, Vol. 236, pp. 69-79

2020

  1. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  2. Return to work guidelines for the COVID-19 pandemic

    Occupational Medicine

  3. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2018

  1. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  2. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

    AIDS, Vol. 29, Núm. 5, pp. 571-581

  3. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: A randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents

    HIV Clinical Trials, Vol. 16, Núm. 2, pp. 72-80

2014

  1. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

2013

  1. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV a randomized trial

    Annals of Internal Medicine, Vol. 159, Núm. 2, pp. 86-96

  2. Longitudinal trends in diagnosis at child and adolescent mental health centres in Madrid, Spain

    European Child and Adolescent Psychiatry

  3. Personality disorders and health problems distinguish suicide attempters from completers in a direct comparison

    Journal of Affective Disorders, Vol. 151, Núm. 2, pp. 474-483

2012

  1. Can the Holmes-Rahe Social Readjustment Rating Scale (SRRS) Be Used as a Suicide Risk Scale? An Exploratory Study

    Archives of Suicide Research, Vol. 16, Núm. 1, pp. 13-28

  2. Worldwide impact of economic cycles on suicide trends over 3 decades: Differences according to level of development. A mixed effect model study

    BMJ Open, Vol. 2, Núm. 3